Biomedical subjects

Chanisada Tuchinda

Publications and source records attributed to Chanisada Tuchinda.

6 recordsLinked to original sources

PubMed2006

Novel emerging sunscreen technologies.

Because of increases in the number of skin cancers diagnosed annually, adverse effects of ultraviolet (UV) rays are being recognized, and major public education programs have been undertaken concerning photoprotection, including the use of sunscreen. In daily life, UV exposure is unavoidable; therefore sunscreen should be used regularly. Development in sunscreen manufacturing has grown tremendously in the last decade. Sunscreen active ingredients now are incorporated into cosmetics products to minimize photoaging changes. With the advances in technologies, many new UV filters have been developed recently. These have improved efficacy and safety. This article reviews these new filters, along with regulatory issues in the United States.

Chemistry, Pharmaceutical↗

PubMed2006

Photoprotection by window glass, automobile glass, and sunglasses.

In daily activity, much time is spent indoors and in vehicles. Although the adverse effect of ultraviolet (UV) radiation is now well recognized and active public education programs on photoprotection have been undertaken, the role of window glass in photoprotection has been rarely addressed. It has been known for some time that window glass filters out UVB and transmits UVA and visible light. Recent developments in the glass industry have resulted in glass that provides broad UV protection without the historically associated loss of visible light transmission. Factors affecting UV-protective properties of glass are glass type, glass color, interleave between glass, and glass coating. In this article, photoprotection by window glass, automobile glass, and sunglasses is reviewed.

Activities of Daily Living↗

PubMed2006

UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States.

BACKGROUND: The efficacy and safety of UVA1 (340-400 nm) phototherapy were established by studies from European countries. PURPOSE: Evaluate experience with UVA1 phototherapy for patients with cutaneous diseases in the United States. METHODS: A retrospective analysis of 92 cases of UVA1-treated cutaneous conditions from four medical centers in the United States was performed. RESULTS: Two-third of the patients showed a fair to good response (26-100% improvement) and one-third of the patients showed a poor response (0-25% improvement). Diseases with a moderate to good response (51-100% improvement) included scleredema adultorum, hand or foot dermatitis, atopic dermatitis, morphea (medium or medium- to high-dose UVA1), systemic sclerosis, and urticaria pigmentosa. Besides tanning, other adverse effects were found in 15% of patients, which include pruritus, erythema, tenderness, and burning sensation. Patients with skin types I-III responded better that those with a darker skin type. CONCLUSION: UVA1 phototherapy is a useful and well-tolerated treatment option for a variety of skin conditions.

Adolescent↗

PubMed2006

Etanercept for chronic progressive cutaneous sarcoidosis.

Sarcoidosis is a chronic, multisystem, granulomatous disease that has various cutaneous manifestations. Chronic cutaneous sarcoidosis can be difficult to manage. Patients often need systemic corticosteroids as well as other immunosuppressive agents, which may be associated with side effects and long-term complications. We report a 43-year-old patient with chronic progressive cutaneous sarcoidosis unsuccessfully treated with systemic steroid and immunosupressive agents whose cutaneous lesions responded significantly to etanercept as monotherapy.

Adult↗

PubMed2006

Life-threatening pustular and erythrodermic psoriasis responding to infliximab.

Pustular and erythrodermic psoriasis can be a debilitating and recalcitrant disease which may result in secondary complications such as sepsis, electrolyte imbalance, renal failure, and heart failure. We report a case of a 46-year-old patient with life-threatening erythrodermic psoriasis who responded rapidly to intravenous infliximab.

Antibodies, Monoclonal↗

PubMed2004

Sweet's syndrome: a reaction to non-tuberculous mycobacterial infections.

Sweet's syndrome has been reported to be associated with many underlying conditions, such as non-tuberculous mycobacterial infections (NTMI). In the literature, only twelve patents with Sweet's syndrome in association with NTMI have been reported (most of the patients were from Thailand). Here, the authors report six more patients who developed Sweet's syndrome as a reaction to NTMI. Four patients had Mycobacterium chelonae/abscessus group infection; one patient had been infected with Mycobacterium avium complex first and became infected with M. chelonae/abscessus group 17 months later; and, the other one had Mycobacterium fortuitum infection. In each patient, the skin lesions of Sweet's syndrome relapsed many times while they still had NTMI, and these lesions usually responded well to short courses of systemic steroids without any deterioration of NTMI.

Adult↗